Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.7752W HIGH $13.56
Volume
3.53 M
Value Traded
126.55 M
Short % Float
5.94%
+2.57%Week
-5.28%1 Month
+9.57%3 Month
+85.46%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.73 B
EPS (TTM)
0.13
P/E Ratio
92.94
Ent. Value
4.79 B
Total Shares
382.15 M
Float Shares
261.15 M
Insiders
31.66%
Institutions
65.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LFST Catalyst Timeline
Dated clinical, regulatory and corporate events for LifeStance Health Group, Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How LFST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
LifeStance Health Group, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LFST program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TPG GP A, LLC10% Owner | Sell | -18,409,705 79,691,702 held | $12.29 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LFST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.3 % | 32.13 M | 3.00 M | -30.23% ( -1.30 M) |
LFST Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LFST ranks across every disease it competes in
Competitive Position is a premium feature
See how LFST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLFST News
-LFST
Oct 15, 2026▼ -1.2%today
LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026
LifeStance Health Group, Inc. will release its third quarter 2026 earnings on November 5, 2026. The company will host a live conference call at 8:30 a.m. ET to discuss the results. Participants can join via phone or access a webcast on the Investor Relations website. A replay will also be available post-call.
Read more →-LFST
Sep 9, 2026LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health Group has announced the pricing of a secondary public offering of 22,250,000 shares at $12.35 per share. The offering is being conducted by certain stockholders, with LifeStance not receiving any proceeds. The company also plans to repurchase 2,000,000 shares from the underwriter. The offering is expected to close on September 11, 2026.
Read more →-LFST
Sep 9, 2026LifeStance Health Group Announces Launch of Secondary Public Offering
LifeStance Health Group announced a secondary public offering of 22,250,000 shares of common stock by certain stockholders. The company will not receive any proceeds from this offering, as the Selling Stockholders will benefit from the sale. Additionally, LifeStance has authorized the repurchase of 2,000,000 shares from the underwriter, contingent on the offering's completion.
Read more →-LFST
Sep 1, 2026LifeStance to Present at Upcoming Investor Conferences
LifeStance Health Group, Inc. will present at two upcoming investor conferences in September 2026. CFO Ryan McGroarty will speak at the Jefferies Healthcare Services and Technology Conference, while CEO Dave Bourdon will present at the Morgan Stanley Healthcare Conference. Both events will be webcast live, with replays available afterward.
Read more →-LFST
Aug 20, 2026LifeStance Health Foundation Renews Partnership with the American Foundation for Suicide Prevention to Advance Mental Health Research
LifeStance Health Foundation has renewed its partnership with the American Foundation for Suicide Prevention (AFSP), committing $100,000 to support clinical research aimed at advancing suicide prevention strategies. This partnership has already raised over $170,000 in its inaugural year, highlighting the urgent need for research in this critical area of mental health. LifeStance will continue to match teammate donations to AFSP, fostering further engagement in suicide prevention initiatives.
Read more →-LFST
Jul 16, 2026LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
LifeStance Health Group, Inc. will release its second quarter 2026 earnings before the market opens on August 6, 2026. The company will host a live conference call at 8:30 a.m. ET to discuss the results. Interested parties can join the call via phone or access a live audio webcast on the Investor Relations website.
Read more →-LFST
May 7, 2026▲ +20.2%on this newsshared move
LifeStance Reports First Quarter 2026 Results
LifeStance Health Group, Inc. reported strong financial results for Q1 2026, with a 21% increase in revenue to $403.5 million and a notable rise in net income to $14.2 million. The company also experienced significant growth in clinician numbers and visit volumes. LifeStance raised its revenue expectations for the full year 2026, indicating robust demand for mental healthcare services.
Read more →-LFST
Apr 16, 2026LifeStance to Host First Quarter 2026 Earnings Conference Call on May 7, 2026
LifeStance Health Group, Inc. will release its first quarter 2026 earnings on May 7, 2026. A live conference call will be held at 8:30 a.m. ET to discuss the results. Participants can join via phone or through a webcast on the company's Investor Relations website. A replay will be available post-call.
Read more →-LFST
Feb 25, 2026LifeStance Reports Fourth Quarter and Full Year 2025 Results
LifeStance Health Group, Inc. announced its financial results for Q4 and full year 2025, highlighting significant revenue growth and a positive net income. The company ended the year with strong cash flow and announced a $100 million share repurchase program. CEO Dave Bourdon expressed optimism about the company's operational momentum heading into 2026.
Read more →-LFST
Feb 10, 2026LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. will release its fourth quarter and full year 2025 earnings on February 25, 2026. A live conference call is scheduled for the same day at 8:30 a.m. ET, where results will be discussed. The call can be accessed via phone or through a webcast on their Investor Relations website.
Read more →-LFST
Nov 6, 2025▲ +29.9%on this news
LifeStance Reports Third Quarter 2025 Results
LifeStance Health Group, Inc. reported strong financial results for the third quarter of 2025, with revenue increasing by 16% year-over-year to $363.8 million. The company achieved a positive net income of $1.1 million, a significant recovery from a net loss of $6.0 million in the previous year. LifeStance also expanded its clinician base by 11%, reaching nearly 8,000 clinicians, and reported an increase in adjusted EBITDA of 31% to $40.2 million. The company reiterated its full-year revenue guidance while raising expectations for center margins and adjusted EBITDA.
Read more →-LFST
Aug 7, 2025LifeStance Reports Second Quarter 2025 Results
LifeStance Health Group, Inc. announced its financial results for Q2 2025, showing an 11% increase in revenue to $345.3 million. The number of clinicians grew by 11%, and visit volumes rose by 12%. The net loss, however, was reduced to $3.8 million from $23.3 million in the previous year, highlighting operational improvements. The company also raised its full-year guidance for revenue and Adjusted EBITDA. Despite these gains, LifeStance faces ongoing challenges in a competitive and regulated healthcare industry.
Read more →-LFST
May 14, 2025LIFESTANCE NAMES VAUGHN PAUNOVICH AS CHIEF TECHNOLOGY OFFICER
LifeStance Health has appointed Vaughn Paunovich as the new Chief Technology Officer, effective June 9, 2025. Paunovich, who has over 25 years of experience in health care technology, will spearhead LifeStance's technology strategy to enhance digital experiences for patients and clinicians. He replaces Pablo Pantaleoni, who played a significant role in the company's digital transformation. The transition reflects LifeStance's ambition to improve access to mental health services across the country.
Read more →-LFST
May 7, 2025▼ -15.9%on this news
LifeStance Reports First Quarter 2025 Results
LifeStance Health Group, Inc. reported its first quarter 2025 financial results, highlighting a revenue increase of 11% to $333.0 million. The company achieved net income of $0.7 million, marking its first positive net income since becoming public, alongside a 10% increase in clinician numbers. However, the company also recorded negative cash flow from operations and free cash flow for the quarter. Looking ahead, LifeStance reaffirmed its revenue and EBITDA guidance for the fiscal year 2025.
Read more →About LifeStance Health Group, Inc. Common Stock
Headquarters4800 N. SCOTTSDALE ROAD, SCOTTSDALE, AZ, 85251
BIOPHARMAWATCH ELITE PLUS
Trade the next LFST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime